{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T17:25:41Z","timestamp":1786123541548,"version":"build-2736575974"},"reference-count":47,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["eJHaem"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Safe outpatient delivery of B\u2010cell maturation antigen\u2013targeting bispecific antibodies (BCMA\u2010BsAbs) in multiple myeloma (MM) is challenging, particularly during step\u2010up dosing (SUD). Standardized guidance for European community practice is limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A modified Delphi methodology panel sought expert consensus on safe, effective outpatient SUD and transition of care from academic to community centers for patients receiving BCMA\u2010BsAbs. A steering committee of 10 European specialists in MM and BCMA\u2010BsAb delivery generated statements based on literature review and clinical experience. Statements were tested in three rounds with a Delphi panel of 53 clinicians (hematologists, nurses, pharmacists) across France, Germany, Italy, Portugal, Spain, and the United Kingdom. Consensus was defined as \u2265 75% agreement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Consensus was achieved for 84 statements. Key recommendations included: (1) patient stability before community center transition (afebrile \u2265 24 h, ASTCT Grade 0 toxicity, stable organ function); (2) community center requirements (training in cytokine release syndrome\/immune effector cell\u2013associated neurotoxicity syndrome, urgent laboratory access, tocilizumab and corticosteroids on\u2010site, 24\/7 escalation protocols); and (3) infection management (baseline cytomegalovirus testing, immunoglobulin [Ig] monitoring, prophylaxis with intravenous\/subcutaneous Ig for IgG &lt; 400 mg\/dL, antiviral\/\n                      <jats:italic>Pneumocystis jirovecii<\/jats:italic>\n                      pneumonia prophylaxis). Outpatient SUD should be restricted to clinically stable patients with low tumor burden and reliable caregiver support and conducted only in centers with staff trained in BCMA\u2010BsAb toxicity management and a clear escalation plan.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This European Delphi consensus provides a structured framework for outpatient SUD and transition of BCMA\u2010BsAb therapy in MM. Adopting these recommendations may improve safety and consistency and expand accessibility.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:label\/>\n                    <jats:p>Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/jha2.70290","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:25:48Z","timestamp":1778743548000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["European Recommendations for Transitioning the Care of Patients With Multiple Myeloma Treated With B\u2010Cell Maturation Antigen Bispecific Antibodies From Academic Hospitals to Community\u2010Based Centers and for Outpatient Step\u2010Up Dosing"],"prefix":"10.1002","volume":"7","author":[{"given":"Mar\u00eda\u2010Victoria","family":"Mateos","sequence":"first","affiliation":[{"name":"University Hospital of Salamanca\/IBSAL\/Cancer Research Center\u2013IBMCC (USAL\u2010CSIC)  Salamanca Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Zamagni","sequence":"additional","affiliation":[{"name":"Istituto Di Ematologia \u201cSer\u00e0gnoli\u201d, IRCCS Azienda Ospedaliero\u2010Universitaria Di Bologna  Bologna Italy"},{"name":"Dipartimento Di Scienze Mediche E Chirurgiche Universit\u00e0 Di Bologna  Bologna Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[{"name":"Hematology Unit, Department of Onco\u2010Hematology A.O. of Cosenza  Cosenza Italy"},{"name":"Department of Pharmacy, Health and Nutritional Science University of Calabria Rende Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Hall","sequence":"additional","affiliation":[{"name":"University Hospitals Dorset NHS Foundation Trust  Bournemouth UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Lachenal","sequence":"additional","affiliation":[{"name":"Groupement Hospitalier Nord\u2010Dauphin\u00e9 (GHND)  Bourgoin\u2010Jallieu France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00f3nica L\u00f3pez","family":"Ri\u00f1on","sequence":"additional","affiliation":[{"name":"Hospital General La Mancha Centro, Alc\u00e1zar de San Juan Ciudad Real Spain"},{"name":"Hospital General de Tomelloso  Tomelloso Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Popat","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Scheid","sequence":"additional","affiliation":[{"name":"Cologne University Hospital  Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Wolff","sequence":"additional","affiliation":[{"name":"Onkologie Lerchenfeld  Hamburg Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Perez\u2010Cruz","sequence":"additional","affiliation":[{"name":"Pfizer Inc. New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint Antoinel Sorbonne University  Paris France"},{"name":"NSERM UMRs938  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571\u2010025\u201001041\u2010x"},{"key":"e_1_2_13_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14213"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(24)00043\u20103"},{"key":"e_1_2_13_5_1","unstructured":"Elrexfio (elranatamab) Summary of Product Characteristics Pfizer Europe MA EEIG(2023)."},{"key":"e_1_2_13_6_1","unstructured":"Tecvayli (Teclistamab) Summary of Product Characteristics Janssen\u2010Cilag International NV(2022)."},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010023\u201002528\u20109"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2203478"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470\u20102045(23)00159\u20106"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010211305"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fepid.2025.1568688"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae321"},{"issue":"4","key":"e_1_2_13_13_1","first-page":"154","article-title":"BCMA\u2010Directed Bispecific Antibodies for Multiple Myeloma: Practical Approaches to Patient Management","volume":"15","author":"Wagner C. B.","year":"2025","journal-title":"Journal of Hematology Oncology Pharmacy"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.24875\/SANGREE.25000033"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.14444"},{"key":"e_1_2_13_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.12.002"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004326"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010023\u201000879\u20107"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.6004\/jadpro.2025.16.7.19"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408\u2010025\u201001282\u20100"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010199374"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152\u20102650(23)01904\u20103"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.Bcd\u201023\u20100049"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco\u201024\u201001893"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/2643\u20103230.BCD\u201024\u20100354"},{"key":"e_1_2_13_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u20104588"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19507"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/op\u201024\u201000489"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152\u20102650(23)01471\u20104"},{"key":"e_1_2_13_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010182166"},{"key":"e_1_2_13_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016911"},{"key":"e_1_2_13_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.04.002"},{"key":"e_1_2_13_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.7517"},{"key":"e_1_2_13_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19504"},{"key":"e_1_2_13_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102025\u2010718"},{"key":"e_1_2_13_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432"},{"key":"e_1_2_13_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152\u20102650(25)03484\u20106"},{"key":"e_1_2_13_38_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e19506"},{"key":"e_1_2_13_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102024\u2010204361"},{"key":"e_1_2_13_40_1","unstructured":"Elrexfio (elranatamab\u2010bcmm). Prescribing information.Pfizer Inc;2025."},{"key":"e_1_2_13_41_1","unstructured":"Tecvayli (teclistamab\u2010cqyv) Prescribing information.Janssen Biotech Inc;2025."},{"key":"e_1_2_13_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523\u2010025\u201001170\u20104"},{"key":"e_1_2_13_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3308"},{"key":"e_1_2_13_44_1","unstructured":"\u201cStudy With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant (MagnetisMM\u20107) \u201dClinicalTrials.gov accessed November 24 2025 https:\/\/clinicaltrials.gov\/study\/NCT05317416."},{"key":"e_1_2_13_45_1","unstructured":"\u201cPhase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC\u20104) \u201dClinicalTrials.gov accessed November 24 2025 https:\/\/clinicaltrials.gov\/study\/NCT05243797."},{"key":"e_1_2_13_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010020\u201007503\u2010y"},{"key":"e_1_2_13_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.03.021"},{"key":"e_1_2_13_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.1038"}],"container-title":["eJHaem"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70290","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jha2.70290","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jha2.70290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:53:35Z","timestamp":1786114415000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jha2.70290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/jha2.70290"],"URL":"https:\/\/doi.org\/10.1002\/jha2.70290","archive":["Portico"],"relation":{},"ISSN":["2688-6146","2688-6146"],"issn-type":[{"value":"2688-6146","type":"print"},{"value":"2688-6146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"2026-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70290"}}